Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/24/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/24/2020.
Displaying: 843 trials in your specialties ()
View trials across your selected specialties

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Daratumumab, Drug: Bortezomib, Drug: Lenalidomide, Drug: Dexamethasone, Drug: Melphalan, Drug: Prednisone, Drug: Carfilzomib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CHU Nancy Brabois, Vandoeuvre Les Nancy, France

Brief Summary

The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.

Study in Subjects With Relapsed/Refractory Follicular Lymphoma

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Relapsed/Refractory Follicular Lymphoma
View Full Trial
INTERVENTION

Drug: Tazemetostat, Drug: Placebo oral tablet, Combination Product: Lenalidomide, Combination Product: Rituximab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Arizona Oncology Associates, PC - HOPE, Phoenix, Arizona, United States

Brief Summary

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy.

KRDI in Transplant-Eligible MM

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Carfilzomib, Drug: Isatuximab, Drug: Lenalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital, Boston, Massachusetts, United States

Brief Summary

This research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant. The names of the study drugs involved in this study are: - Carfilzomib - Isatuximab - Lenalidomide - Dexamethasone

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Acute Myeloid Leukemia in Remission
View Full Trial
INTERVENTION

Drug: Azacitidine, Drug: Lenalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing, Jiangsu, China

Brief Summary

Great progress has been witnessed on the treatment of acute myeloid leukemia (AML) in recent years. However, elderly patients ineligible for receiving high dose chemotherapy and allo-HSCT, have high relapse rate and treatment-related complications. Azacitidine (AZA), a listed hypomethylating agent in China in 2018, is the only approved demethylating drug in the treatment of AML, following the NCCN guidelines. In addition, lenalidomide(LEN) has been shown to rapidly enhance cytotoxic T- and natural killer (NK)-cell function and reduce relapse post-chemotherapy in patients with MM, also has substantial activity as a single agent in elderly patients with AML. Measurable residual disease (MRD) has been proven to be highly prognostic in quite a number clinical studies. This study is aimed to validate the efficacy and safety advantages of the maintenance therapy that contain AZA and LEN in elderly or unfit for intensive therapy patients with AML based on MRD monitoring.

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Lenalidomide, Drug: Daratumumab, Behavioral: Questionnaires

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

Brief Summary

The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare giving the usual maintenance therapy (lenalidomide) with giving daratumumab as maintenance therapy, and they will look at which drug gives participants a better health-related quality of life during treatment. The researchers will measure participants' quality of life using various questionnaires. This study will help researchers find out whether this different approach of giving daratumumab as maintenance therapy is better, the same as, or worse than the usual approach.

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Carfilzomib, Drug: Lenalidomide, Drug: Dexamethasone, Drug: Daratumumab, Procedure: autologous hematopoietic cell transplantation

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

Brief Summary

The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Ce...
View Full Trial
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Dexamethasone Sodium Phosphate, Drug: Lenalidomide, Drug: MDM2 Inhibitor KRT-232

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Brief Summary

This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving MDM2 Inhibitor KRT-232, lenalidomide, carfilzomib, and dexamethasone together may work better in treating patients with multiple myeloma.

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Refractory Large B-cell Lymphoma
View Full Trial
INTERVENTION

Biological: Axicabtagene Ciloleucel, Drug: Rituximab, Drug: Lenalidomide, Drug: Fludarabine, Drug: Cyclophosphamide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

Brief Summary

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    EBV Infection
View Full Trial
INTERVENTION

Drug: PD1 antibody, Drug: lenalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Brief Summary

The present study was a prospective one-arm clinical study, in which EBV-HLH/chronic active EBV infection patients were selected as the main subjects to evaluate the effect of PD-1 antibody and lenalidomide regimens on ebv-dna and safety.

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Carfilzomib/Lenalidomide/Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CHU de Toulouse, Toulouse, France

Brief Summary

The purpose is to determine whether induction and consolidation treatment with Carfilzomib, Lenalidomide and Dexamethasone (CRd), within an intensive program, warrant further investigation in clinical trials.